ページ4 - トルコで最高の腫瘍科医師 - トップ200名の医師

Dr. Mehmet Doğu Canoğlu is a radiation oncologist. He graduated from Kocaeli University Faculty of Medicine. He completed his residency in radiation oncology at Kocaeli University from 2006 to 2012.

He completed his compulsory service at Diyarbakır Training and Research Hospital. He then worked at Bağcılar Training and Research Hospital and at Medipol Mega University Hospital from 2015 to 2017. Since 2017, he has been a radiation oncologist at Anadolu Medical Center.

プロフェッサー ネジデット・ユシュケントは、アンカラ大学医学部を卒業しました。彼はアンカラGATA医学校で内科医学のレジデンシー研修を修了しました。彼はアメリカのテキサス州ダラスで医療用腫瘍学および血液学の臨床フェローシップ研修を行いました。トルコで最初の移植を実施した骨髄移植チームに参加しました。異なる時期に、彼はロンドンのウェストミンスター病院 チャリングクロス、ハマースミス、ロイヤル フリー、ユニバーシティ カレッジ 病院で長期間の客員講師を務め、スイスのバーゼル カントン病院でも講義しました。欧州医学腫瘍学会（ESMO）によって主催された試験に合格し、彼はヨーロッパ医学腫瘍学証明書を取得しました。トルコ医学腫瘍学会の7人の創設会員の1人として、プロフェッサー ユシュケントはトルコ腫瘍学グループ（TOG）の創設者でもありました。

学歴

大学 

アンカラ大学医学部, アンカラ 1971 

専門教育 

GATA 医学校, アンカラ 1979 
 

ワドレー分子医学研究所, グランビル・モートンがん病院, 医療用腫瘍学および血液学のサブスペシャリティ, 1982

助教

GATA 医学校, 医療用腫瘍学クリニック, アンカラ 1984 

准教授 

GATA 医学校, 医療用腫瘍学クリニック, アンカラ 1989 

教授 

GATA, 医療用腫瘍学および血液学クリニック, イスタンブール 2001

専門分野

• 乳がん
• 胃腸がん
• 肺がん
• リンパ腫
• 骨髄腫
  
  所属機関
  
  トルコ医学腫瘍学会
• トルコ血液学会
• 肺がん学会
• 免疫腫瘍学会
• 神経腫瘍学会
• 乳がん学会
• イスタンブール胃腸がんグループ
• イスタンブールリンパ腫グループ
• イスタンブール骨髄腫グループ
• 欧州医学腫瘍学会（ESMO）
• 米国臨床腫瘍学会

Prof. Dr. Kamil Yalçın Polat is a leading transplantology expert and Head of the Organ Transplantation Center at Memorial Bahçelievler Hospital in Istanbul. With over 30 years of surgical experience, he founded the Organ Transplantation Center at Atatürk University (2003-2010) and completed fellowships at Mount Sinai Hospital and Memorial Sloan Kettering Cancer Center in New York. Dr. Polat has authored more than 50 scientific publications and serves as Vice President of the Turkish Hepatopancreatobiliary Surgery Society.

Dr. Mustafa Ozdogan is a Professor and Medical Oncology Specialist at Memorial Göztepe Hospital (2025–present). He previously led the Oncology Department at Memorial Antalya Hospital (2013–2025). He also led the Oncology Department at Medstar Antalya Hospital (2012–2025). Earlier, he served at Akdeniz University (2003–2012).

Education and titles: MD, Erciyes University (1993). Internal Medicine residency, Akdeniz University (1996–2000). Medical Oncology fellowship (2000–2003). Associate Professor (2006). Professor (2011).

Professional memberships and roles: Member of ESMO and ASCO. Board Member of the Turkish Society of Medical Oncology. Co‑Chair of the Head and Neck Cancers Working Group (Medical Oncology Society). President of the Antalya Breast Cancer Association. Member of the Turkish Oncology Workshop.

2018 - Present, Istanbul/Istanbul/Türkiye

MEMORIAL BAHCELIEVLER HOSPITAL

Radiation Oncology Specialist

1986 - Present, Istanbul/Istanbul/Türkiye

ISTANBUL UNIVERSITY CERRAHPAŞA MEDICAL FACULTY

Radiation Oncology Specialist

2015 - 2018, Istanbul/Istanbul/Türkiye

MEMORIAL SISLI HOSPITAL

Radiation Oncology Specialist

2018 - Present, Istanbul/Istanbul/Türkiye

MEMORIAL BAHCELIEVLER HOSPITAL

Medical Oncology Specialist

2018 - 2018, Istanbul/Istanbul/Türkiye

ISTANBUL AYDIN UNIVERSITY MEDICAL PARK FLORYA HOSPITAL

Medical Oncology Specialist

2015 - 2018, Istanbul/Istanbul/Türkiye

HASEKİ TRAINING AND RESEARCH HOSPITAL

Medical Oncology Specialist

2011 - 2014, Istanbul/Istanbul/Türkiye

ISTANBUL SCIENCE UNIVERSITY INTERNAL MEDICINE DEPARTMENT

Medical Oncology Assistant

2011 - 2011, Istanbul/Istanbul/Türkiye

KANUNİ SULTAN TRAINING AND RESEARCH HOSPITAL

Internal Medicine Specialist

2006 - 2011, Istanbul/Istanbul/Türkiye

ISTANBUL TRAINING AND RESEARCH HOSPITAL

Internal Medicine Assistant

2004 - 2005, Istanbul/Istanbul/Türkiye

ISTANBUL UNIVERSITY CERRAHPAŞA MEDICAL FACULTY BIOCHEMISTRY UNITED STATES

Research Assistant

2003 - 2004, Karabuk/Karabuk/Türkiye

KARABUK PROVINCE SAFRANBOLU NO. 3 HEALTH CENTER

General Practitioner

38年の経験 脳神経外科を専門とし、Akalan教授はメディポル・メガ大学病院においてO-armイメージングシステムなどの先進技術を駆使しています。

• 小児てんかんおよびグリオーマ症例を専門とする
• 脳神経外科に関する117本の学術論文を発表
• 『Advances and Technical Standards in Neurosurgery』の共著者
• 超音波ガイド下技術を用いて合併症を最小限に抑える

2018 - Present, Istanbul/Istanbul/Türkiye

MEMORIAL BAHCELIEVLER HOSPITAL

Radiation Oncology Specialist

2016 - 2018, Istanbul/Istanbul/Türkiye

ISTANBUL UNIVERSITY CERRAHPAŞA MEDICAL FACULTY

Radiation Oncology Specialist

Education and Expertise

Selcuk University Meram Faculty of Medicine - Medical Education

Dr.Abdurrahman Yurtaslan Anakara Oncology Training and Research Hospital Medical Oncology Specialization

Experience

Malatya State Hospital Internal Diseases Clinic

Ankara Oncology Hospital Medical Oncology Clinic

Erzurum Regional Training and Research Hospital Medical Oncology Clinic


AREAS OF INTEREST

Lung cancer

esophageal cancer

Gastric cancer

breast cancer

Gastrointestinal surgery

https://scholar.google.com.tr/citations?user=EDuylhoAAAAJ&hl=tr 

トルコトップクラスの肉腫専門医であるアフメット・ビリチ博士は、メディポル・メガ大学病院において希少かつ複雑な症例を専門に診療しています。

• 28年の経験 の腫瘍内科専門医としての経験
• 肺癌および肉腫治療のエキスパート
• メディポル大学医療腫瘍学教授
• 患者の医療文書を自ら精査

Dr. Sefik Igdem is a respected radiation oncologist with 37 years of experience. He is known for his skill in advanced cancer treatments. Dr. Igdem specializes in radiotherapy, intensity-modulated radiation therapy, 3D conformal radiation therapy, and image-guided radiotherapy. He focuses mainly on prostate cancer and head and neck cancers.

Dr. Igdem has played a key role in bringing new technologies and conformal treatments to radiation oncology. He has also completed a retrospective analysis of 600 postmenopausal breast cancer cases. This work shows his commitment to evidence-based care. His broad clinical experience and focus on innovation have made him a leader in his field.

この医師は39年の経験を持つ核医学専門医であり、現在はMedipol Mega University Hospitalで診療を行っています。この医師はGazi Universityで教授職を務め、Ankara Order Laboratoryの核医学部門のディレクターを務めました。この医師はトルコ核医学協会およびヨーロッパ核医学協会のメンバーです。この医師は1984年にErciyes University Faculty of Medicineを卒業し、1992年にAnkara Universityで核医学専門医となりました。

Education:

Teaching course on “Lymphatic mapping and sentinel node”

June 1998, MDA Cancer Center, Houston, Texas, USA

General Surgery

Feb. 1993 – Dec. 1996, Şişli Etfal Hospital, Istanbul, Turkey

General Surgery

May 1990 – Jan. 1993, Lille University Hospital, Lille, France 

M.D.

1983 – 1990, Cerrahpasa School of Medicine, Istanbul, Turkey

Experience

Attending General Surgeon, Jan. 1998 – present 

F.N. Metropolitan Hospital, Istanbul, Turkey

American Cancer Center, Breast Surgery

Attending General Surgeon, 1996 – present 

Medmar Diagnostic Center, Istanbul, Turkey

Diagnosis and monitoring with sophisticated techniques 

General Surgeon, 1996 – 1998

Guzelbahce Medical Center and Yeditepe Hospital, Istanbul, Turkey

Specializing in breast and thyroid surgery

• 2021 - Currently, Istanbul/Turkey
  MEMORIAL ŞİŞLİ HOSPITAL
  Dermatology Specialist
• 2021 - Currently, Istanbul/Turkey
  MEMORIAL ATAŞEHİR HOSPITAL
  Dermatology Specialist
• 2013 - 2021, Istanbul/Turkey
  MEDENİYET UNIVERSITY
  Lecturer
• 2013 - 2016, Istanbul/Turkey
  MEDENİYET UNIVERSITY
  Head of Department
• 2013 - 2014, Istanbul/Turkey
  MEDENİYET UNIVERSITY
  Director of the Institute of Health Sciences
• 2012 - 2012, /ABD
  PITTSBURGH UNIVERSITY
  Visiting Scholar
• 2010 - 2013, Erzurum/Turkey
  ATATURK UNIVERSITY MEDICAL FACULTY
  Professor, Lecturer, Dermatology Specialist
• 2001 - 2007, Van/Turkey
  YUZUNCU YIL UNIVERSITY
  Assistant Professor, Dermatology Specialist

• 2019 - Currently, Istanbul/Turkey
  MEMORIAL ATAŞEHİR HOSPITAL
  Obstetrician and Gynecologist - Gynecological Oncology Surgery
• 2017 - 2019, Istanbul/Turkey
  ISTANBUL MEDENIYET UNIVERSITY GÖZTEPE TRAINING AND RESEARCH HOSPITAL
  Gynecological Oncology Surgery Center
• 2012 - 2017, Istanbul/Turkey
  ZEYNEP KAMIL WOMEN HEALTH AND PEDIATRICS TRAINING AND RESEARCH HOSPITAL
  Gynecology and Obstetrics Specialist
• 2008 - 2012, Bursa/Turkey
  MUSTAFAKEMALPAŞA PUBLIC HOSPITAL
  Gynecology and Obstetrics Specialist
• 2004 - 2008, Erzincan/Turkey
  ERZINCAN PUBLIC HOSPITAL
  Gynecology and Obstetrics Specialist

Education and Specialization

2017 Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Department of Internal Medicine

19 November 2020 Istanbul University Istanbul Faculty of Medicine, Department of Medical Oncology

2011-25 June 2015 Hospitals / Istanbul Haydarpasa Numune Education and Research Hospital

2004 Mersin University Faculty of Medicine

Experience

13.11.2017-29.03.2021 Istanbul University Istanbul Faculty of Medicine Internal Medicine Departments, Department of Internal Medicine

21.03.2011-25.06.2015 Istanbul Haydarpasa Numune Education and Research Hospital



Ferhatoğlu Ferhat, Çağatay Tulin, Okumuş Nigar Gülfer, Aydıner Adnan, Paksoy Nail, Ak Naziye, Aydın Esra, Saip Pinar Mualla (2023). Laterality Of Adrenal Gland Metastasis In Lung Cancer: Results Of A Comparative Study. Eurasian Journal Of Medical Investigatin, 7(2), 101-106., Doi: 10.14744/Ejmi.2023.58954

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

TAŞTEKİN DİDEM, PAKSOY NAİL, DOĞAN İZZET, FERHATOĞLU FERHAT, KHANMAMMADOV NIJAT, BOZBEY HAMZA UGUR, KARABULUT SENEM (2023). Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first?line treatment of metastatic gastric cancer: A single?center experience. Journal of Cancer Research and Therapeutics, 19(2), 253-258., Doi: 10.4103/jcrt.jcrt_672_22 (Quarterly=Q4)

KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340

KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340

FERHATOĞLU FERHAT, AYDINER ADNAN, PAKSOY NAİL (2022). Evaluation of clinical features and risk factors related to late recurrence (>5 years) in patients with breast cancer. Journal of Surgery and Medicine, 6(12), 986-990., doi: 10.28982/josam.7610

FERHATOĞLU FERHAT, ERTÜRK KAYHAN, TAŞ FARUK (2022). Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences. Journal of Cancer Research and Therapeutics, 0, Doi: 10.4103/jcrt.jcrt_815_21

ÖZGÜR EMRE, FERHATOĞLU FERHAT, ŞEN FATMA, GEZER UĞUR (2022). Effect of Cytotoxic Therapy on ALU Expression is Modulated by Hormonal Status in Patients with Breast Cancer. BALKAN MEDICAL JOURNAL, 39(6), 450-451., Doi: 10.4274/balkanmedj.galenos.2022.2022-5-18

Articles

TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Auricular and periauricular melanomas have similar clinicopathologic factors and survival rates. JOURNAL OF COSMETIC DERMATOLOGY, 21(4), 1570-1573., Doi: 10.1111/jocd.14278

TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Completion Lymph Node Dissection Is Unnecessary After Positive Sentinel Lymph Node in Melanoma — a Case Series Analysis. Indian Journal of Surgery, Doi: 10.1007/s12262-022-03532-y

DOĞAN İZZET, GÜRBÜZ MUSTAFA, PAKSOY NAİL, FERHATOĞLU FERHAT, VATANSEVER SEZAİ, SAİP PINAR, DEMİRKAZIK AHMET, AYDINER ADNAN (2022). Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC. Medicine, 101(34), 30188, Doi: 10.1097/MD.0000000000030188

PAKSOY NAİL, KHANMAMMADOV NIJAT, DOĞAN İZZET, FERHATOĞLU FERHAT, YILDIZ ANIL, AK NAZİYE, AYDINER ADNAN (2022). Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study. Medicine, 101(45), 31726, Doi: 10.1097/MD.0000000000031726

PAKSOY NAİL, FERHATOĞLU FERHAT, DOĞAN İZZET, KHANMAMMADOV NIJAT, İRİBAŞ ÇELİK AYÇA, GÜLBAŞ ZAFER, BAŞARAN MERT (2022). High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing's sarcoma: A single institution experience. Medicine, 101(49), 32213, Doi: 10.1097/MD.0000000000032213

ÇİL İBRAHİM, KÜÇÜKARDA AHMET, ATCI MUHAMMED MUSTAFA, SECMELER SABAN, PAKSOY NAİL, FERHATOĞLU FERHAT, AK NAZİYE, AYHAN MURAT, TATAROĞLU ÖZYÜKSELER DENİZ, ÖNDER ARİF HAKAN, AVCI OKAN, OYMAN ABDİLKERİM, OKTEN ILKER NIHAT, GÜLTÜRK İLKAY, AKAGÜNDÜZ BARAN, BASOĞLU TÜYLÜ TUĞBA, ÇAKIR EMRE, HACIBEKİROĞLU İLHAN, ÖZÇELİK MELİKE, AYDINER ADNAN (2022). Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori Journal, 108(1), 19-25., Doi: 10.1177/03008916211037739

DOĞAN İZZET, KARABULUT SENEM, TAŞTEKİN DİDEM, FERHATOĞLU FERHAT, PAKSOY NAİL, ŞAKAR BURAK (2022). Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer. Journal of the College of Physicians and Surgeons Pakistan, 32(8), 1014-1019., Doi: 10.29271/jcpsp.2022.08.1014

FERHATOĞLU FERHAT, TUĞCU MURAT, APAYDIN SÜHEYLA (2022). Factors Affecting Postoperative Morbidity and Mortality in Chronic Hemodialysis Patients. Eurasian Journal of Medical Advances, 2(3), 30-38., doi: 10.14744/ejma.2022.43153

KAPAĞAN TANJU, FERHATOĞLU FERHAT, RETIRED SELİNAY, KILIÇ ÇAĞLA ECEM (2022). Risk Factors for Cutaneous Melanomas and Level of Awareness in Society. Journal of the Turkish Academy of Dermatology, 16(4), 94-100., Doi: 10.4274/jtad.galenos.2022.30092

FERHATOĞLU FERHAT, ALTAN FERHATOĞLU ZEYNEP (2022). Frequency, Demographic and Clinicopathological Characteristics of Skin Cancer Patients Treated and Followed Up in the Medical Oncology Outpatient Clinic. Journal of the Turkish Academy of Dermatology, 16(4), 77-81., Doi: 10.4274/jtad.galenos.2022.04706

KARABULUT SENEM, DOĞAN İZZET, USUL AFŞAR ÇİĞDEM, KARABULUT MEHMET, KARAMAN ŞULE, FERHATOĞLU FERHAT, TAŞTEKİN DİDEM (2021). Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 27(6), 1357- 1363., Doi: 10.1177/1078155220959427

AK NAZİYE, ÖZKAN BERKER, YENİGÜN BÜLENT MUSTAFA, YILMAZBAYHAN EMİNE DİLEK, TOKER SEYFİ ALPER, FERHATOĞLU FERHAT, YAŞAR HATIME ARZU, DİZBAY SAK SERPİL, TANJU SERHAT, DILEGE MUSTAFA ŞÜKRÜ, ERUS SUAT, BULUTAY PINAR, FIRAT PINAR, MANDEL NİL MOLİNAS, KILIÇKAP SAADETTİN, ONDER SEVGEN, DİKMEN ERKAN, ALAN ÖZKAN, YUMUK PERRAN FULDEN, BOZKURTLAR EMİNE, LAÇİN TUNÇ, YILDIZELİ BEDRETTİN, ÖZTÜRK AKIN, KOCATÜRK CELALETTİN İBRAHİM, KARAPINAR KEMAL, ÜRER HALIDE NUR, OYAN ULUÇ BAŞAK, AYDINER ADNAN, DEMİRKAZIK AHMET, ERALP YEŞİM (2021). The role of adjuvant chemotherapy in resected stage I non-small cell lung cancer: A Turkish Oncology Group Study.. Journal of BUON, 26(3), 819-829.

AK NAZİYE, TOKER SEYFİ ALPER, KARA MURAT, ÖZKAN BERKER, ÜLKER MELİKE GÜLER, KABA ERKAN, YEGEN GÜLÇİN, KARAMAN ŞULE, DAĞOĞLU SAKİN RABİA NERGİZ, KAYTAN SAGLAM ESRA, ORAL ETHEM NEZİH, KİZİR AHMET, BAYRAKTAR SOLEY, DİSTÇİ RIAN, FERHATOĞLU FERHAT, AYDIN ESRA, VATANSEVER SEZAİ, ERALP YEŞİM, AYDINER ADNAN (2021). Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center. TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 29(4), 487- 495., Doi: 10.5606/tgkdc.dergisi.2021.20529

AK NAZİYE, PAKSOY NAİL, FERHATOĞLU FERHAT, AYDIN ESRA, DOĞAN İZZET, BEKTAŞ ERDEM, KARACA MERT, OGUZ SOYDİNÇ HİLAL, MINARECİ YAĞMUR, SÖZEN HAMDULLAH, TOPUZ SAMET, SAİP PINAR MUALLA, VATANSEVER SEZAİ (2021). Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma. TURKISH JOURNAL of ONCOLOGY, 36(4), 438-445., Doi: 10.5505/tjo.2021.2882

Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.

Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.